Parsippany, NJ, March 24, 2026 (Yahoo Finance) -- Embecta has agreed to acquire Owen Mumford to strengthen its drug-delivery business. The transaction, valued at approximately $300 million, will add a range of injection and medical device products to Embecta’s portfolio. The deal is expected to enhance the company’s capabilities in supporting patients with chronic conditions. Read full article here .

Brisbane, CA, April 7, 2026 (ImpediMed) — ImpediMed has named Erik Anderson as its new chief executive officer. The leadership change is intended to guide the company’s strategic direction and support expansion of its medical technology portfolio. The appointment comes as ImpediMed focuses on advancing its commercial operations and growth initiatives. Read full article here .

San Diego, CA, April 7, 2026 (Yahoo Finance) -- Neurocrine Biosciences has outlined a transaction valued at approximately $2.9 billion aimed at expanding its therapeutic portfolio. The deal is designed to enhance the company’s pipeline with additional clinical-stage assets. The move supports Neurocrine’s strategy to drive long-term growth through targeted business development initiatives. Read full article here .

Marlborough, MA and New York, NY, April 7, 2026 (Business Wire) -- Hologic announced the close of its go-private acquisition by Blackstone and TPG at up to $79/share and simultaneously named José (Joe) Almeida as CEO, effective immediately. Almeida was previously Chairman/President/CEO of Baxter International (2016–2025) and before that CEO of Covidien through its Medtronic acquisition. He succeeds Steve MacMillan, who retired after 12+ years. Read full article here .

Foster City, CA and Munich, Germany, April 7, 2026 (Business Wire) -- Gilead Sciences has announced plans to acquire Tubulis to enhance its cancer treatment portfolio. The deal includes $3.15 billion in upfront cash, along with potential milestone payments that could bring the total value significantly higher. The acquisition adds advanced antibody-drug conjugate (ADC) candidates and platform technologies aimed at strengthening Gilead’s next-generation oncology pipeline. Re

Chicago, IL, March 18, 2026 (Business Wire) -- GE HealthCare has finalized its $2.3 billion acquisition of Intelerad, a provider of medical imaging software solutions. The addition strengthens its presence in cloud-based imaging and extends capabilities into ambulatory and teleradiology markets. The company expects the business to generate substantial recurring revenue in its first full year under ownership. Read full article here .

Boston, MA, March 23, 2026 (Globe Newswire) -- Damora Therapeutics has appointed Jennifer Jarrett as president and chief executive officer, effective at the end of March. She brings extensive experience from prior leadership roles in biotech and investment banking. The company aims to leverage her expertise to advance its biologics pipeline for blood disorders. Read full article here .

Foster City, CA, March 23, 2026 (Business Wire) -- Gilead Sciences has entered an agreement to acquire Ouro Medicines in a deal valued at up to $1.7 billion. The acquisition is designed to enhance its development of T-cell engager therapies targeting autoimmune diseases. Integrating Ouro’s platform is expected to accelerate progress on novel immunology treatments. Read full article here .

Cardiff-by-the-Sea, CA, March 16, 2026 (PR Newswire) -- Field Medical has named Mark A. Turco, MD, as its new chief executive officer. He brings decades of leadership experience across cardiovascular and medical device companies. The appointment is intended to advance the company’s pulsed field ablation technology for treating complex cardiac arrhythmias. Read full article here .

Rahway, NJ and Foster City, CA, March 25, 2026 (Business Wire) -- Merck has agreed to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion. The deal adds TERN-701, an investigational oral therapy for chronic myeloid leukemia, to Merck’s oncology pipeline. The transaction is expected to close in the second quarter of 2026, pending customary conditions. Read full article here .

Santa Clara, CA & San Francisco, CA, March 9, 2026 (Business Wire) -- Agilent Technologies announced it has agreed to acquire Biocare Medical for $950 million in cash, expanding its portfolio in clinical and research pathology solutions. Biocare develops antibodies, reagents, and instruments used in technologies such as immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH), and generated over $90 million in revenue in 2025 wh

Dedham, MA, March 1, 2026 (Business Wire) -- Qlaris Bio has appointed Fred Guerard, Pharm.D., as president and chief executive officer, effective March 1, 2026, and he will also join the company’s board of directors. Guerard brings more than 20 years of leadership experience in ophthalmology and biotechnology, with a focus on advancing innovative therapies through late-stage development and commercialization. He succeeds Thurein Htoo, who helped establish the company and ad